Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.

MLA

O’Donoghue, Michelle L., et al. “Prognostic Utility of Secretory Phospholipase A(2) in Patients with Stable Coronary Artery Disease.” Clinical Chemistry, vol. 57, no. 9, Sept. 2011, pp. 1311–17. EBSCOhost, https://doi.org/10.1373/clinchem.2011.166520.

APA

O’Donoghue, M. L., Mallat, Z., Morrow, D. A., Benessiano, J., Sloan, S., Omland, T., Solomon, S. D., Braunwald, E., Tedgui, A., & Sabatine, M. S. (2011). Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clinical Chemistry, 57(9), 1311–1317. https://doi.org/10.1373/clinchem.2011.166520

Chicago

O’Donoghue, Michelle L, Ziad Mallat, David A Morrow, Joelle Benessiano, Sarah Sloan, Torbjørn Omland, Scott D Solomon, Eugene Braunwald, Alain Tedgui, and Marc S Sabatine. 2011. “Prognostic Utility of Secretory Phospholipase A(2) in Patients with Stable Coronary Artery Disease.” Clinical Chemistry 57 (9): 1311–17. doi:10.1373/clinchem.2011.166520.